09Dec
07Dec
SC Launch, Inc. Announces Third Investment in Zylö Therapeutics
South Carolina Research Authority (SCRA’s) investment affiliate, SC Launch, Inc. has made its third investment into Zylö Therapeutics, Inc. This $300,000 investment will help the company continue providing therapeutic topical solutions. Read more >>
19Nov
Silo Pharma and Strategic Partner Zylo Therapeutics Begin Development Process for Novel Ketamine Loaded Z-Pods
Silo Pharma, Inc. a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that their joint venture partner Zylo Therapeutics received its first ketamine shipment and initiated loading ketamine into their Z-Pod® transdermal technology. Read more >>
11Nov
Zylö’s Erectile Dysfunction Product Concept Wins Best Abstract Award
A novel nitric-oxide-releasing product concept developed by Zylö Therapeutics was awarded Best Abstract - Basic Science at the annual scientific meeting of the North American Sexual Medicine Society of North America (SMSNA), held October 21-24 in Scottsdale. Read more>>
08Oct
Silo Pharma achieves milestone – Partner Zylo Therapeutics Receive DEA Approval to Advance Silos time released Ketamine technology
Silo Pharma, Inc. a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that their joint venture partner Zylo Therapeutics received approval from the DEA to advance the development of their Z-pod technology in combination with Ketamine. Read more >>
04Sep
NEXT Venture Pitch finalists
...Billed as the “premiere venture pitch of the Carolinas,” NEXT gives entrepreneurs a chance to pitch ideas to investors, venture capitalists and community leaders. One of the six finalists is: Zylö Therapeutics — Next-gen, topical drug delivery systems. Read more >>
12Aug
Silo Pharma Announces that JV partner Zylo Therapeutics Successfully Completes Initial Inspection for Ketamine Intradermal Research
Silo Pharma, Inc., a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that Silo’s joint venture partner, ZYLO Therapeutics, completed its first inspection with the SC Board of Pharmacy and will move forward with the Department of Health and Environmental Control. Read more >>
21Jul
Zylö Receives $1,700,000 NIH Phase II Grant to Advance Erectile Dysfunction Program into Human Trials
Zylö Therapeutics Inc., developer of the transformational Z-pod™ topical delivery platform, has been awarded a $1,700,000 Small Business Innovation Research (SBIR) grant to advance Zylö’s proprietary nitric-oxide-releasing topical drug candidate into clinical trials. Read more >>
20May
Zylö and Amifar Laboratorios Forge Broad-Ranging Partnership
Zylö Therapeutics Inc., developer of the transformational Z-pod™ topical delivery platform, announced that it has entered into a broad-ranging agreement with Amifar Laboratorios Spain to supply Z-pods to further enhance Amifar’s new line of advanced cosmetics. Amifar and Zylö have initiated a product development collaboration beginning with two actives and have plans to expand the list of actives over time. Read more >>
22Dec